Home
    Disclaimer
    ← Back to Ephenidine
    Ephenidine molecular structure

    Ephenidine Stats & Data

    Dissociative Research-chemical
    Epe Nedpa
    PubChem CID 110821
    NPS DataHub
    MW225.33
    FormulaC16H19N
    CAS60951-19-1
    IUPACN-Ethyl-1,2-diphenylethylamine
    SMILESCCNC(Cc1ccccc1)c1ccccc1
    InChIKeyIGFZMQXEKIZPDR-UHFFFAOYSA-N
    Phenethylamines; Arylalkylamines; 2020/1. Von 2-Phenethylamin abgeleitete Verbindungen; 2021/1. Von 2-Phenethylamin abgeleitete Verbindungen; 2022/1. Von 2-Phenethylamin abgeleitete Verbindungen
    Psychoactive Class Dissociative
    Half-Life Unknown in humans (no published human PK). Functional effects commonly persist for 4–8 h with after-effects up to 24 h depending on dose and route.

    Receptor Profile

    Receptor Actions

    Agonists
    Sigma-1 receptor agonist (Ki = 629 nM)
    Sigma-2 receptor agonist (Ki = 722 nM)
    Antagonists
    NMDA receptor antagonist (Ki = 66 nM)
    Inhibitors
    Dopamine transporter inhibitor (Ki = 379 nM)
    Norepinephrine transporter inhibitor (Ki = 841 nM)

    History & Culture

    Ephenidine emerged on the research chemical market in early 2015 as a dissociative anesthetic sold through online vendors as a designer drug. It was marketed as a potentially smoother alternative to other diarylethylamine dissociatives that were legally available at the time, particularly diphenidine and methoxphenidine, which had gained a reputation for producing comparatively harsh experiences. As a relatively unknown research chemical, ephenidine has very little documented history of human usage. The lack of formal research into the substance means that most pharmacological understanding has been derived from its structural similarities to related dissociatives rather than from direct scientific investigation of the compound itself. Its status as a structural isomer of the banned opioid lefetamine complicated its legal standing in some jurisdictions from the outset, leading several countries to move relatively quickly toward scheduling the substance despite its brief presence on the market.

    Subjective Effects

    Physical

    The subjective physical effects of ephenidine can be broken down into several components which progressively intensify proportional to dosage.

    • Tactile disconnection
    • Spontaneous tactile sensations: The ephenidine body high is a soft and pleasurable tingling sensation which is motionless and all-encompassing with no specific location.
    • Stimulation: This compound provides stimulating effects at lower dosages which are less intense than that of diphenidine or methoxphenidine.
    • Tactile suppression: This partially to entirely suppresses one's sense of touch, creating feelings of numbness within the extremities. It is responsible for the anaesthetic properties of this substance.
    • Motor control loss: A loss of gross and fine motor control alongside of balance and coordination is prevalent within the ephenidine experience and becomes especially strong at higher doses. This means that one should be sitting down before the onset (unless one is experienced) in case of falling over and injuring oneself.
    • Decreased bodily weight: This creates the sensation that the body is floating and has become entirely weightless. This effect is strangely stimulating and encourages physical activities at low to moderate doses by making the body feel light and effortless to move.
    • Physical autonomy
    • Increased heart rate
    Cognitive

    The general head space of ephenidine is often described as particularly euphoric and clear-headed in comparison to that of DXM and ketamine.

    • Depersonalization
    • Derealization
    • Consciousness disconnection
    • Memory suppression
    • Thought deceleration
    • Information processing suppression
    • Time distortion
    • Euphoria
    • Introspection
    • Déjà vu
    • Conceptual thinking
    • Compulsive redosing
    • Anxiety suppression
    • Disinhibition
    • Amnesia
    • Unity and interconnectedness
    Sensory

    This substance does not enhance visual stimuli; instead, it tends to degrade and decrease visual aptitude in a variety of ways.

    Auditory
    • Enhancements
    • Suppression
    • Distortions
    • Hallucinations
    Visual · Distortions

    Ephenidine exhibits a full array of dissociative distortions and alterations in visual perception.

    • Visual drifting: (melting, flowing, breathing and morphing) - In comparison to other dissociatives, this effect is more prominent than ketamine, MXE, diphenidine and methoxphenidine. The visual drifting is simplistic, slow and smooth in motion, static in appearance and unrealistic/cartoon-like in style.
    • Perspective distortions
    • Scenery slicing
    Visual · Hallucinatory States

    At high doses, ephenidine can produce a full range of high level hallucinatory states in a fashion that is less consistent and reproducible than that of many other commonly used psychedelics.

    • Internal hallucinations: (autonomous entities, settings, sceneries, and landscapes, alterations in perspective and scenarios and plots) - In comparison to other dissociatives, this effect can occur at heavy dosages, but is considerably less common than the same effect found within psychedelics and deliriants. It can be comprehensively described as delirious in believability, fixed in style, equal in new experiences and memory replays in content, autonomous in controllability and solid in style.
    Visual · Suppressions
    • Visual disconnection: This eventually results in the ephenidine equivalent of the famous 'k-hole' or, more specifically, holes, spaces and voids alongside of structures. However, it is worth noting that particularly heavy dosages must be consumed to reach the deepest state of this component in comparison to other more classical dissociatives such as ketamine or methoxetamine.
    • Visual acuity suppression
    • Double vision: This component is prevalent at moderate to heavy dosages and makes reading impossible unless one closes an eye.
    • Pattern recognition suppression: This effect generally occurs at higher dosages and makes one unable to recognize and interpret perceivable visual data.

    Forked from Subjective Effect Documentation by Josie Kins, July 2015. Via dose.wiki (CC0).

    Toxicity

    PsychonautWiki

    The toxicity and long-term health effects of recreational ephenidine use do not seem to have been studied in any scientific context and the exact toxic dosage is unknown. This is because ephenidine has very little history of human usage. Anecdotal reports from those who have tried ephenidine suggest that there do not seem to be any negative health effects attributed to simply trying this drug at low to moderate doses by itself and using it sparingly (but nothing can be completely guaranteed). Independent research should always be done to ensure that a combination of two or more substances is safe before consumption. It is strongly recommended that one use harm reduction practices when using this substance.

    Effect Profile

    Curated + 16 Reports
    Dissociative 7.1

    Strong dissociative depth, mania, insight, and motor impairment

    Dissociative Depth×3
    10
    Mania / Compulsion×1
    10
    Insight / Novel Thought×2
    10
    Motor / Sensory Impairment×1
    10
    Based on reports from:
    Effect Index The Polychrome Sea — nervewing Bluelight Big & Dandy Thread Erowid Experience Reports PsychonautWiki Ephenidine The Drug Users Bible Ephenidine

    Duration Timeline

    Bluelight
    Onset Comeup Peak Offset After Effects
    Oral
    10-30 minutes
    30 minutes - 1.0 hours
    1-3 hours
    2-4 hours
    2-6 hours
    Total: 5-7 hours
    Rectal
    10-19 minutes
    19-40 minutes
    1-3 hours
    2-4 hours
    2-6 hours
    Total: 3-6 hours

    Community Effects

    TripSit
    Positive
    visual enhancement stimulation relaxation sociability dissociation
    Negative
    anxiety tachycardia confusion

    Tolerance & Pharmacokinetics

    drugs.wiki
    Half-Life
    Unknown in humans (no published human PK). Functional effects commonly persist for 4–8 h with after-effects up to 24 h depending on dose and route.
    Addiction Potential
    Low-to-moderate psychological reinforcement; compulsive redosing reported by some. Rapid tolerance and occasional dysphoria tend to limit continuous use.

    Tolerance Decay

    Full tolerance 3d Half tolerance 7d Baseline ~14d

    Estimates reflect strong, rapid cross-tolerance typical of NMDA antagonists; values are extrapolated from dissociative literature and user reports rather than controlled human PK studies.

    Cross-Tolerances

    Ketamine
    60% ●○○
    Methoxetamine (MXE)
    60% ●○○
    Diphenidine and related diarylethylamines
    70% ●○○

    Experience Report Analysis

    Erowid
    16 Reports
    2014–2019 Date Range
    16 With Age Data
    21 Effects Detected

    Demographics

    Gender Distribution

    Age Distribution

    Reports Over Time

    Effect Analysis

    Erowid

    Effects aggregated from 16 experience reports (16 Erowid)

    16 Reports
    21 Effects Detected
    9 Positive
    5 Adverse
    7 Neutral

    Effect Sentiment Distribution

    Confidence Distribution

    Positive Effects 9

    Stimulation 68.8% 70%
    Euphoria 56.2% 70%
    Color Enhancement 50.0% 70%
    Music Enhancement 50.0% 70%
    Focus Enhancement 43.8% 70%
    Empathy 37.5% 70%
    Body High 31.2% 70%
    Tactile Enhancement 25.0% 70%
    Pain Relief 18.8% 70%

    Adverse Effects 5

    Anxiety 50.0% 70%
    Confusion 43.8% 70%
    Nausea 31.2% 70%
    Motor Impairment 31.2% 70%
    Memory Suppression 18.8% 70%

    Dosage Distribution

    Dose distribution from experience reports

    Median: 100.0 mg IQR: 70.0–150.0 mg n=10

    Real-World Dose Distribution

    62K Doses

    From 25 individual dose entries

    Oral (n=20)

    Median: 100.0mg 25th: 70.0mg 75th: 120.0mg 90th: 150.0mg
    mg/kg median: 1.529 mg/kg 75th: 1.837

    Form / Preparation

    Most common forms and preparations reported

    Body-Weight Dosing

    Dose relative to body weight from reports with weight data

    Median: 1.52 mg/kg IQR: 1.403–1.838 mg/kg n=9

    Redose Patterns

    Redosing behavior across 15 reports

    53.3% Redosed
    1.9 Avg Doses
    180m Median Interval
    Read full reports on Erowid →

    Legal Status

    Country Status Notes
    United Kingdom Grey area (as of 2015) As of 2015 sources, ephenidine was legally available through online research chemical vendors as a designer drug. It was marketed alongside similar diarylethylamine compounds such as diphenidine and methoxphenidine. Sources cautioned that this grey area status did not guarantee immunity from prosecution, as legality was likely to vary and could change.

    Harm Reduction

    drugs.wiki

    Ephenidine is a selective NMDA receptor antagonist at the PCP site (Ki ≈ 66 nM) with modest activity at DAT/NET and sigma sites; this explains dissociation with a lightly stimulating edge in some users. Oral onset can be slow and sometimes delayed beyond 60 minutes, which increases the temptation to redose early—waiting a full 2 hours before any redose lowers the risk of overshooting. Residual stimulation, cognitive fog, and trouble sleeping can persist into the next day following strong doses; plan dosage timing accordingly (avoid late-evening starts if sleep is important). Compared with arylcyclohexylamines like ketamine, diarylethylamines have less defined data on urinary toxicity; nonetheless, users have reported bladder/urinary discomfort after heavy or frequent use—staying well-hydrated, spacing sessions widely, and stopping if urinary symptoms appear is prudent. Insufflation is frequently reported as harsh and irritating with a large chemical drip and shorter, less predictable effects; many users prefer oral or carefully prepared rectal solutions to reduce local irritation. Mixing with alcohol, GHB/GBL, or opioids markedly increases the risk of loss of consciousness, vomiting, and respiratory depression; these combinations account for many serious dissociative-related emergencies. Combining with stimulants increases heart rate and blood pressure and can precipitate anxious or manic states, particularly when sleep is missed. Dissociatives strongly impair balance and depth perception—set up a safe environment, avoid heights/water, and do not drive or cycle during or after use until fully baseline. Rapid, pronounced cross-tolerance exists across NMDA antagonists; frequent use quickly blunts effects and encourages dose escalation—spacing sessions by several weeks reduces risk. Community reagent-testing anecdotes suggest ephenidine may give an orange→brown Marquis and green Mandelin reaction; however, reagent kits cannot prove identity—use a professional drug checking service when possible.

    References

    Data Sources

    Cited References

    Additional references

    ← Back to Ephenidine